Showing results (11-20 of 32) with videos related to

Sort By:
Pageof 4
Oncotarget|November 22, 2017
Circulating tumor DNA shows variable clonal response of breast cancer during neoadjuvant chemotherapyJi-Yeon Kim, Donghyun Park, Dae-Soon Son, et al.
Rheumatology (Oxford, England)|December 19, 2022
Efficacy of subcutaneous vs intravenous infliximab in rheumatoid arthritis: a post-hoc analysis of a randomized phase III trialArnaud Constantin, Roberto Caporali, Christopher J Edwards, et al.
NPJ Breast Cancer|August 30, 2023
Deep learning model improves tumor-infiltrating lymphocyte evaluation and therapeutic response prediction in breast cancerSangjoon Choi, Soo Ick Cho, Wonkyung Jung, et al.
Arthritis Research & Therapy|April 17, 2021
Comparative efficacy of subcutaneous (CT-P13) and intravenous infliximab in adult patients with rheumatoid arthritis: a network meta-regression of individual patient data from two randomised trialsBernard Combe, Yannick Allanore, Rieke Alten, et al.
Discover Oncology|November 20, 2024
Changes in the tumor microenvironment in recurrent head and neck squamous cell carcinoma and its implication on efficacy of immune checkpoint inhibitorsDong Hyun Kim, Mingu Kang, Gahee Park, et al.
Diagnostics (Basel, Switzerland)|October 27, 2022
Artificial Intelligence-Powered Whole-Slide Image Analyzer Reveals a Distinctive Distribution of Tumor-Infiltrating Lymphocytes in Neuroendocrine NeoplasmsHyung-Gyo Cho, Soo Ick Cho, Sangjoon Choi, et al.
Genome Biology|July 23, 2017
Characterization of background noise in capture-based targeted sequencing dataGahee Park, Joo Kyung Park, Seung-Ho Shin, et al.
Cells|September 27, 2024
Comparison of Tumor Microenvironments between Primary Tumors and Lymph Node Metastases in Head and Neck Squamous Cell Carcinoma and Their Predictive Role in Immune Checkpoint Inhibitor TreatmentDong Hyun Kim, Jong Seok Ahn, Mingu Kang, et al.
Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology|January 4, 2026
PD-L1 expression combined with immune phenotype is a potential predictor of outcome with PD-1 inhibitor monotherapy in patients with recurrent or metastatic head and neck squamous cell carcinomaDong Hyun Kim, Jiwon Koh, Jong Seok Ahn, et al.
Histopathology|March 13, 2024
An artificial intelligence-powered PD-L1 combined positive score (CPS) analyser in urothelial carcinoma alleviating interobserver and intersite variabilityKyu Sang Lee, Euno Choi, Soo Ick Cho, et al.
Pageof 4